Cite
Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma.
MLA
Lee, Inki, et al. “Early Response Monitoring of Neoadjuvant Chemotherapy Using [18F]FDG PET Can Predict the Clinical Outcome of Extremity Osteosarcoma.” EJNMMI Research, vol. 10, no. 1, Jan. 2020, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s13550-019-0588-4.
APA
Lee, I., Byun, B. H., Lim, I., Kim, B. I., Choi, C. W., Koh, J.-S., Song, W. S., Cho, W. H., Kong, C.-B., & Lim, S. M. (2020). Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma. EJNMMI Research, 10(1), 1–9. https://doi.org/10.1186/s13550-019-0588-4
Chicago
Lee, Inki, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Jae-Soo Koh, Won Seok Song, Wan Hyeong Cho, Chang-Bae Kong, and Sang Moo Lim. 2020. “Early Response Monitoring of Neoadjuvant Chemotherapy Using [18F]FDG PET Can Predict the Clinical Outcome of Extremity Osteosarcoma.” EJNMMI Research 10 (1): 1–9. doi:10.1186/s13550-019-0588-4.